Table 3.
Demographic data.
| Diagnosis | Male: Female (ratio) | Median age, years (IQR†) | Ethnicity (%) | Median time from the onset of erythroderma to the first evaluation, months (IQR) | Median time of follow-up, months (IQR) |
|---|---|---|---|---|---|
| Psoriasis | 36:16 (2.2) | 48 (36.5–57) | White: 36 (69.2) | 2.0 (1.0–5.0) | 51.6 (15.5–84.9) |
| Black: 7 (13.5) | |||||
| Brown: 9 (17.3) | |||||
| Yellow: 0 | |||||
| Eczema | 43:21 (2.0) | 60.5 (53–71.5) | White: 33 (51.6) | 4.0 (2.0–8.0) | 16.2 (4.1–51.9) |
| Black: 16 (25.0) | |||||
| Brown: 14 (21.9) | |||||
| Yellow: 1 (1.6) | |||||
| AD | 19:8 (2.4) | 25 (19–32)* | White: 13 (48.1) | 1.5 (1.0–7.0)* | 53.7 (9.9–107.4) |
| Black: 5 (18.5) | |||||
| Brown: 8 (29.6) | |||||
| Yellow: 1 (3.7) | |||||
| Drug-induced | 23:15 (1.5) | 62.5 (47–71) | White: 32 (84.2) | 1.0 (1.0–3.0)* | 12.7 (3.9–29.7) |
| Black: 3 (7.9) | |||||
| Brown: 3 (7.9) | |||||
| Yellow: 0 | |||||
| SS | 22:16 (1.4) | 62.5 (54–70) | White: 26 (68.4) | 11.0 (4.0–24.3) | 14.1 (7.3–33.9) |
| Black: 5 (13.1) | |||||
| Brown: 7 (18.4) | |||||
| Yellow: 0 | |||||
| MF | 13:4 (3.2) | 58 (51–69) | White: 6 (35.3) | 12.0 (3.2–24.3) | 28.0 (14.4–89.2) |
| Black: 1 (5.9) | |||||
| Brown: 9 (52.9) | |||||
| Yellow: 1 (5.9) | |||||
| Miscellaneous | 14:7 (2.0) | 56 (45–63) | White: 15 (71.4) | 6.0 (2.0–12.0) | 18.0 (6.2–31.7) |
| Black: 1 (4.8) | |||||
| Brown: 5 (23.8) | |||||
| Yellow: 0 | |||||
| Idiopathic | 43:9 (4.8) | 68 (57–77) | White: 23 (44.2) | 4.5 (3.0–10.0) | 14.4 (5.4–31.9) |
| Black: 11 (21.1) | |||||
| Brown: 14 (26.9) | |||||
| Yellow: 4 (7.7) | |||||
| Total | 213:96 (2.2) | 57 (45–70) | White: 184 (59.5) | 4.0 (1.0–10.0) | 18.5 (6.5–54.0) |
| Black: 49 (15.9) | |||||
| Brown: 69 (22.3) | |||||
| Yellow: 7 (2.3) |
†IQR: interquartile range.
*P = 0.0001.